Literature DB >> 30552836

Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features.

Gian Marco Moneta1, Denise Pires Marafon1, Emiliano Marasco1, Silvia Rosina2, Margherita Verardo1, Chiara Fiorillo2, Carlo Minetti3, Luisa Bracci-Laudiero4, Angelo Ravelli3, Fabrizio De Benedetti1, Rebecca Nicolai1.   

Abstract

OBJECTIVE: To evaluate the expression of type I interferon (IFNα/β)- and type II IFN (IFNγ)-inducible genes in muscle biopsy specimens from patients with juvenile dermatomyositis (DM) and to correlate their expression levels with histologic and clinical features.
METHODS: Expression levels of IFN-inducible genes and proinflammatory cytokines were assessed by quantitative polymerase chain reaction in muscle biopsy specimens from patients with juvenile DM (n = 39), patients with Duchenne's muscular dystrophy (DMD), and healthy controls. Muscle biopsy sections were stained and scored for severity of histopathologic features. The charts of patients with juvenile DM were reviewed for clinical features at the time of sampling and long-term outcomes.
RESULTS: Muscle expression levels of IFNα/β-inducible genes (type I IFN score), IFNγ, IFNγ-inducible genes (type II IFN score), and tumor necrosis factor (TNF) were significantly higher in juvenile DM patients not receiving glucocorticoid therapy before muscle biopsy (n = 27) compared to DMD patients (n = 24) (type I IFN score, P < 0.0001; type II IFN score, P < 0.001; TNF, P < 0.05) and healthy controls (n = 4) (type I IFN score, P < 0.01; type II IFN score, P < 0.01; TNF, P < 0.05). Immunofluorescence staining of muscle biopsy sections from untreated juvenile DM patients showed increased immunoreactivity for IFNγ and HLA class II molecules compared to controls. Type I and type II IFN scores were correlated with typical histopathologic features of juvenile DM muscle biopsy samples, such as infiltration of endomysial CD3+ cells (type I IFN score, r = 0.68; type II IFN score, r = 0.63), perimysial CD3+ cells (type I IFN score, r = 0.59; type II IFN score, r = 0.66), CD68+ cells (type II IFN score, r = 0.46), and perifascicular atrophy (type I IFN score, r = 0.61; type II IFN score, r = 0.77). Juvenile DM patients with a high type I IFN score, a high type II IFN score, and high TNF expression levels showed more severe disease activity at biopsy (P < 0.05). In addition, juvenile DM patients with a high type II IFN score at biopsy reached clinically inactive disease significantly later than patients with low type II IFN score (log rank chi-square value 13.53, P < 0.001).
CONCLUSION: The increased expression of IFN-inducible genes in the muscle in juvenile DM patients and their association with histologic and clinical features further support a pathogenic role for both type I and type II IFNs in juvenile DM.
© 2018, American College of Rheumatology.

Entities:  

Year:  2019        PMID: 30552836     DOI: 10.1002/art.40800

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  19 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 2.  Advances Toward Precision Medicine in Juvenile Dermatomyositis.

Authors:  Jessica Neely; Susan Kim
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 3.  [Recent research on tofacitinib in the treatment of pediatric rheumatic diseases].

Authors:  Shi-Hai Zhou; Ya-Qun Xiong; Ya Chen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

Review 4.  Type I Interferons in Autoimmunity.

Authors:  Ruth Fernandez-Ruiz; Timothy B Niewold
Journal:  J Invest Dermatol       Date:  2022-01-10       Impact factor: 8.551

5.  Apremilast in Recalcitrant Cutaneous Dermatomyositis: A Nonrandomized Controlled Trial.

Authors:  Carole Bitar; Thien Ninh; Katherine Brag; Soraya Foutouhi; Stella Radosta; Jade Meyers; Melody Baddoo; Delong Liu; Brittany Stumpf; Paul W Harms; Nakhle S Saba; Erin Boh
Journal:  JAMA Dermatol       Date:  2022-10-05       Impact factor: 11.816

6.  A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis.

Authors:  Q-L Peng; Y-M Zhang; L Liang; X Liu; L-F Ye; H-B Yang; L Zhang; X-M Shu; X Lu; G-C Wang
Journal:  Clin Exp Immunol       Date:  2019-12-18       Impact factor: 4.330

7.  Comparison of Lesional Juvenile Myositis and Lupus Skin Reveals Overlapping Yet Unique Disease Pathophysiology.

Authors:  Jessica L Turnier; Lauren M Pachman; Lori Lowe; Lam C Tsoi; Sultan Elhaj; Rajasree Menon; Maria C Amoruso; Gabrielle A Morgan; Johann E Gudjonsson; Celine C Berthier; J Michelle Kahlenberg
Journal:  Arthritis Rheumatol       Date:  2021-05-02       Impact factor: 15.483

Review 8.  Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis.

Authors:  Simon Rothwell; Hector Chinoy; Janine A Lamb
Journal:  Curr Opin Rheumatol       Date:  2019-11       Impact factor: 5.006

Review 9.  Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.

Authors:  Hanna Kim
Journal:  Curr Opin Rheumatol       Date:  2021-09-01       Impact factor: 4.941

10.  Co-expression network analysis reveals the pivotal role of mitochondrial dysfunction and interferon signature in juvenile dermatomyositis.

Authors:  Danli Zhong; Chanyuan Wu; Jingjing Bai; Dong Xu; Xiaofeng Zeng; Qian Wang
Journal:  PeerJ       Date:  2020-02-18       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.